Pneumocystis Pneumonia during Rituximab Treatment in Children with Autoimmune Nerve System Diseases
- 155 Downloads
Rituximab is an anti-CD20 monoclonal antibody which eliminates B lymphocytes in peripheral blood. Pneumocystis pneumonia is an opportunistic infection caused by pneumocystis jirovecii. Defect in cell-mediated immunity is the primary cause of pneumocystis pneumonia. Some studies have reported occurrence of pneumocystis pneumonia after rituximab use in cancer, hematopoietic cells transplantation and systemic rheumatologic diseases. Thus far, only one case suffering from pneumocystis pneumonia during treatment autoimmune nervous system disease with rituximab was reported. This patient was treated concurrently with high doses of corticosteroid and cyclophosphamide (Garcia-Moreno et al. 2016). Thus, whether pneumocystis pneumonia was related with rituximab was unclear.
In pediatric neurological department of Peking University First Hospital, a total of 79 paediatric patients were diagnosed with nervous system autoimmune diseases and treated with rituximab with follow-up median...
We thank Prof. Russell C. Dale of the Children’s Hospital at Westmead, University of Sydney for the great ideas in this study and the revision for this paper.
Compliance with Ethical Standards
The study was approved by the Ethics Committee of the Peking University First Hospital.
Patients were gave written informed consent.
Conflict of Interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan PA, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M (2014) Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 83:142–150CrossRefPubMedPubMedCentralGoogle Scholar
- Jiang X, Mei X, Feng D, Wang X (2015) Prophylaxis and treatment of pneumocystis jiroveci pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis. PLoS One 10:e122171Google Scholar